AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Y+L amino acid transporter 1 including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Y+L amino acid transporter 1 therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Y+L amino acid transporter 1, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on Y+L amino acid transporter 1. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Y+L amino acid transporter 1. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for Y+L amino acid transporter 1 includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Y+L amino acid transporter 1
partner:
Reaxense
upacc:
Q9UM01
UPID:
YLAT1_HUMAN
Alternative names:
Monocyte amino acid permease 2; Solute carrier family 7 member 7; y(+)L-type amino acid transporter 1
Alternative UPACC:
Q9UM01; B2RAU0; D3DS26; O95984; Q53XC1; Q86U07; Q9P2V5
Background:
Y+L amino acid transporter 1, also known as Solute carrier family 7 member 7, plays a crucial role in the transport of cationic amino acids across cell membranes. It functions as a heterodimer with SLC3A2, facilitating the efflux of cationic amino acids in exchange for neutral amino acids and sodium ions. This process is vital for nitric oxide synthesis and arginine transport in non-polarized cells, such as monocytes, essential for their proper function.
Therapeutic significance:
Y+L amino acid transporter 1's malfunction is linked to Lysinuric Protein Intolerance (LPI), a metabolic disorder characterized by poor nutrient absorption and severe systemic symptoms. Understanding the role of Y+L amino acid transporter 1 could open doors to potential therapeutic strategies for treating LPI, emphasizing the importance of targeted research in this area.
